<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011373</article-id><article-id pub-id-type="publisher-id">ACM-38529</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_62914001.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  微卫星不稳定性与结直肠癌及癌前病变相关性研究进展
  Research Progress on the Relationship between Microsatellite Instability and Colorectal Cancer and Precancerous Lesions
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>雪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邹</surname><given-names>佳芮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>宝华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>亚楠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>解</surname><given-names>水杉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郝</surname><given-names>俊梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>滨州医学院烟台附属医院病理科，山东 烟台</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2471</fpage><lpage>2477</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    结直肠癌(Colorectal cancer)是常见的恶性肿瘤之一，其发病率逐年增高。结直肠癌的发病原因与发病机制十分复杂，由错配修复系统(MMR)异常导致的微卫星不稳定性(MSI)与结直肠癌的发生存在着密切联系，这为结直肠癌诊断与治疗提供了许多思路与方法，其中不少MSI相关的结直肠癌的诊断与治疗方法已应用于临床实践中，特别是Lynch综合征的筛选对于患者及其亲属癌症的早期诊断和治疗至关重要。本文将从MSI及其发生机制、MSI与CRC及癌前病变的相关性和MSI检测方法等方面展开，就MSI与CRC及癌前病变相关性的研究进展做一综述。
    Colorectal cancer (CRC) is one of the common malignant tumors, and its incidence is increasing year by year. The pathogenesis and pathogenesis of colorectal cancer are very complicated. The microsatellite instability (MSI) caused by the abnormality of the mismatch repair system (MMR) is closely related to the occurrence of colorectal cancer, which is the diagnosis and treatment of colorectal cancer. Many ideas and methods are provided. Many of the diagnosis and treatment methods of MSI-related colorectal cancer have been applied in clinical practice. In particular, the screening of Lynch syndrome is very important for the early diagnosis and treatment of cancer of patients and their relatives. This article will review the correlation between MSI and CRC and precancerous lesions. 
  
 
</p></abstract><kwd-group><kwd>微卫星不稳定性，结直肠癌，错配修复系统，Lynch综合征，癌前病变, Microsatellite Instability</kwd><kwd> CRC</kwd><kwd> MSS</kwd><kwd> Lynch Syndrome</kwd><kwd> Precancerous Lesions</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>结直肠癌(Colorectal cancer)是常见的恶性肿瘤之一，其发病率逐年增高。结直肠癌的发病原因与发病机制十分复杂，由错配修复系统(MMR)异常导致的微卫星不稳定性(MSI)与结直肠癌的发生存在着密切联系，这为结直肠癌诊断与治疗提供了许多思路与方法，其中不少MSI相关的结直肠癌的诊断与治疗方法已应用于临床实践中，特别是Lynch综合征的筛选对于患者及其亲属癌症的早期诊断和治疗至关重要。本文将从MSI及其发生机制、MSI与CRC及癌前病变的相关性和MSI检测方法等方面展开，就MSI与CRC及癌前病变相关性的研究进展做一综述。</p></sec><sec id="s2"><title>关键词</title><p>微卫星不稳定性，结直肠癌，错配修复系统，Lynch综合征，癌前病变</p></sec><sec id="s3"><title>Research Progress on the Relationship between Microsatellite Instability and Colorectal Cancer and Precancerous Lesions</title><p>Xue Zheng<sup>*</sup>, Jiarui Zou, Baohua Li, Ya’nan Zhang, Shuishan Xie, Junmei Hao<sup>#</sup></p><p>Department of Pathology, Yantai Affiliated Hospital of Binzhou Medical College, Yantai Shandong</p><p><img src="//html.hanspub.org/file/7-1571650x5_hanspub.png" /></p><p>Received: Oct. 11<sup>th</sup>, 2020; accepted: Nov. 2<sup>nd</sup>, 2020; published: Nov. 9<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/7-1571650x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Colorectal cancer (CRC) is one of the common malignant tumors, and its incidence is increasing year by year. The pathogenesis and pathogenesis of colorectal cancer are very complicated. The microsatellite instability (MSI) caused by the abnormality of the mismatch repair system (MMR) is closely related to the occurrence of colorectal cancer, which is the diagnosis and treatment of colorectal cancer. Many ideas and methods are provided. Many of the diagnosis and treatment methods of MSI-related colorectal cancer have been applied in clinical practice. In particular, the screening of Lynch syndrome is very important for the early diagnosis and treatment of cancer of patients and their relatives. This article will review the correlation between MSI and CRC and precancerous lesions.</p><p>Keywords:Microsatellite Instability, CRC, MSS, Lynch Syndrome, Precancerous Lesions</p><disp-formula id="hanspub.38529-formula10"><graphic xlink:href="//html.hanspub.org/file/7-1571650x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/7-1571650x8_hanspub.png" /> <img src="//html.hanspub.org/file/7-1571650x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>结直肠癌是常见的消化系统肿瘤，是导致癌症死亡的第二大原因。收入水平不同的国家，其发病率也显著不同。结直肠癌多见于西方发达国家，近年来，高收入水平的发达国家结直肠癌发病率已趋于稳定，而发展中国家结直肠癌的发病率却急剧增加。据估计，2018年全球约有180万例新发病例，其发生率在女性中居于第二位，在男性中居于第三位 [<xref ref-type="bibr" rid="hanspub.38529-ref1">1</xref>]。从发病机制上来看，除了常见的APC，KRAS，TP53，SMAD4等基因突变促进腺瘤癌变外，微卫星不稳定性发挥着一定作用；从发病形式来看，结直肠癌可分为散发性结直肠癌和遗传性结直肠癌。散发性结直肠癌约占75%，遗传性结直肠癌可达25%，其中，遗传性结直肠癌(CRC)综合征占所有结直肠癌病例的2%~5%，而Lynch综合征是遗传性结直肠癌(CRC)最常见的原因，在所有结直肠癌中占比约为3%。</p></sec><sec id="s6"><title>2. MSI及其发生机制</title><p>微卫星(MS)是短串联的DNA重复序列，分布于整个基因组的编码和非编码区，含有1~6个碱基。在DNA合成过程中，聚合酶的滑移会导致微卫星的突变，最常见的错误类型是碱基错配和插入缺失。这些错误通常通过DNA错配修复(MMR)系统检测和纠正，由MMR基因的突变或甲基化引起的MMR活性不足(dMMR)可导致基因组水平上的超可变表型，称为微卫星不稳定性(MSI)。</p><p>DNA错配修复(MMR)系统中的蛋白包括MLH1，PMS2，MSH2，MSH6，MLH3，MSH3，PMS1和Exo1等，起主要作用的MMR蛋白有：MLH1，MSH2，MSH6和PMS2。当核苷酸复制出现错误时，首先，必需蛋白MSH2与其主要配体MSH6 (或MSH3)结合形成异二聚体复合物，识别新复制的DNA中的核苷酸错配；而另一种必需蛋白MLH1与其主要配体PMS2 (或PMS1或MLH3)形成的二聚体被招募到MSH2配体复合物中；随后，增殖的细胞核抗原蛋白激活MLH1配体复合物，切除错配的DNA核苷酸；最后，重新合成并连接为正确的DNA序列，完成修复过程 [<xref ref-type="bibr" rid="hanspub.38529-ref2">2</xref>]。</p><p>当四种蛋白质(MLH1、PMS2、MSH2或MSH6)中的一种丧失功能，则MMR系统功能丧失，继而致使复制保真度丧失和突变积累，这种超突变的特征导致了dMMR/MSI的发生 [<xref ref-type="bibr" rid="hanspub.38529-ref3">3</xref>]。</p></sec><sec id="s7"><title>3. MSI与结直肠癌及Lynch综合征的相关性</title><p>散发性结直肠癌的分子发病机制是异质性的，多个基因参与了癌变的过程，较为经典的是APC基因突变所导致的一系列致癌过程 [<xref ref-type="bibr" rid="hanspub.38529-ref4">4</xref>]。此外，约15%的散发性结直肠癌中存在微卫星不稳定，其中，80%~90%是由MLH1基因启动子高甲基化所致的沉默表达引起的，是一种与CpG岛甲基化表型相关的现象(CIMP+) [<xref ref-type="bibr" rid="hanspub.38529-ref5">5</xref>]。</p><p>遗传性结直肠癌中有一部分表现为综合征的形式，主要包括：Lynch综合征(LS)和某些息肉病综合征：家族性腺瘤性息肉病(FAP)，MUTYH相关性息肉病，Peutz-Jeghers综合征，青少年息肉病和Cowden/PTEN错构瘤综合征等。其中，与MSI关系最为密切的是Lynch综合征。</p><p>Lynch综合征是由于“MLH1，MSH2，MSH6和PMS2”四个DNA错配修复基因中的一个或多个发生原发性(胚系)突变而产生的。当这种遗传性突变与正常等位基因的散在性体细胞突变相结合，会导致DNA错配修复系统缺陷，从而引起微卫星基因长度变化突变的积累，即所谓的“微卫星不稳定性” [<xref ref-type="bibr" rid="hanspub.38529-ref6">6</xref>]。</p><p>Vincent [<xref ref-type="bibr" rid="hanspub.38529-ref7">7</xref>] 及其同事的研究显示：Lynch综合征相关的微卫星不稳定性结直肠癌的种系突变中，MLH1占45%、MSH2占45%、MSH6占比 ≤ 10%，另外，约有1%~3%的患者为上皮细胞粘附分子(EPCAM)基因缺乏。大多数LS病例可归因于MLH1，MSH2，PMS2或MSH6等四个MMR基因中的胚系杂合突变，其中MLH1和MSH2的胚系缺陷在所有的LS突变中占比约为80%，而PMS2和MSH6缺陷占LS所有突变的10%~20% [<xref ref-type="bibr" rid="hanspub.38529-ref8">8</xref>]。</p></sec><sec id="s8"><title>4. MSI与结直肠癌前病变的相关性</title><p>结直肠癌的发生发展过程是一个连续的多步骤突变过程，绝大多数是由癌前病变进展而来，结直肠癌前病变包括：传统腺瘤、锯齿状病变和炎性肠病等。研究表明：70%的CRC来自散发性腺瘤和FAP中的腺瘤–癌序列，30%来自其他途径，主要包括Lynch综合征中的MMR基因缺陷、无蒂锯齿状病变中的BRAF突变以及MUTYH相关息肉综合征中的基底切除修复基因(BER)缺陷 [<xref ref-type="bibr" rid="hanspub.38529-ref9">9</xref>]。</p><p>在所有结直肠癌的癌前病变中，与MSI关系最密切的为锯齿状病变。结直肠锯齿状病变是指肠上皮以锯齿状/星形结构为特征的病变。2019版WHO消化系统肿瘤将锯齿状病变分为：1) 增生性息肉(HP)，又分为：微泡型增生性息肉(MVHP)和富于杯状细胞型增生性息肉(GCHP)；2) 无蒂锯齿状病变(SSL)；3)无蒂锯齿状病变伴异型增生(SSLD)；4) 传统锯齿状腺瘤(TSA)；5) 锯齿状腺瘤，未分化。其中，HP，尤其是近端结肠的MVHP可能是SSL的前期病变；GCHPs和某些MVHPs也可能进展为TSA。</p><p>高达30%的结直肠癌是由锯齿状致癌通路引起的，锯齿状致癌通路主要涉及BRAF和KRAS突变两条途径 [<xref ref-type="bibr" rid="hanspub.38529-ref10">10</xref>]。在癌变过程中，相关基因的CpG岛甲基化发挥了重要作用。其中，MLH1启动子CpG岛甲基化是大多数的无蒂锯齿状病变进展为癌的关键步骤，部分不伴异型增生的无蒂锯齿状病变通过MLH1甲基化发展为MLH1缺陷型无蒂锯齿状病变伴异型增生，最终进展为伴MSI的散发性结直肠癌。</p><p>Lynch综合征患者相关腺瘤的基因改变比较复杂，除了MMR基因缺陷外还可伴有其它基因(如：APC、CTNNB1等)的改变，这种复杂性导致了Lynch综合征患者结直肠癌发生的分子途径的多样性。</p><p>Ahadova [<xref ref-type="bibr" rid="hanspub.38529-ref11">11</xref>] 等人总结了Lynch综合征结直肠癌发生的三种分子途径：1) 发生MMR缺陷的MMR缺陷型隐窝病灶(MMR-DCF)通过CTNNB1基因突变激活WNT通路，直接进展为结直肠癌，此为主要的分子途径；2) 发生MMR缺陷的MMR缺陷型隐窝病灶(MMR-DCF)获得APC基因的突变，首先发展为MMR缺陷型腺瘤，再进展为结直肠癌。3) MMR功能完整型腺瘤经过二次打击变为MMR缺陷型腺瘤，最终发展为结直肠癌。</p><p>与上述第三种分子途径基本一致的是：Ma [<xref ref-type="bibr" rid="hanspub.38529-ref12">12</xref>] 等人在Lynch综合征相关的一小部分低度腺瘤中发现了MMR功能完整型。这可能是因为LS患者出生时等位基因中已有一个发生突变，而此时其MMR还能够行使正常功能，由于APC等基因的突变导致腺瘤的发生，一旦当其遭受“二次打击”时，另一MMR等位基因也发生突变，此时MMR缺陷。因此，在这一部分患者中，Ma等认为MMR缺陷是晚期腺瘤的特征，是从腺瘤发展到癌的早期步骤。</p><p>Parag D. Dabir [<xref ref-type="bibr" rid="hanspub.38529-ref13">13</xref>] 等人通过对LS患者的腺瘤进行荟萃分析和系统评价，发现了腺瘤中存在DNA错配修复缺陷(dMMR)和微卫星不稳定性(MSI)的危险因素，在LS队列中，通过对dMMR/MSI筛查常规腺瘤可检测出69.5%的LS患者，但目前尚不明确将其用于筛查Lynch综合征(LS)患者是否可行。</p></sec><sec id="s9"><title>5. MSI检测方法</title><p>MSI的检测方法主要有免疫组化技术(IHC)、聚合酶链反应技术(PCR)和二代测序等技术方法。</p><p>免疫组织化学法(IHC)：IHC是通过检测细胞中错配修复蛋白的表达，对标本的MSI状态进行推测，其检测结果与MSI高度一致。临床工作中常联合使用MLH1、MSH2、PMS2和MSH6等抗体来进行检测。判读标准如下：在正常上皮细胞、淋巴细胞、间质细胞等对照组织中等-强阳性的背景下，只要MMR四个蛋白在肿瘤细胞核着色即可判为MMR蛋白阳性表达。当四个MMR蛋白均阳性表达时，可判为微卫星稳定(MSS)；当四个MMR蛋白只有一个表达缺失，可判为低度微卫星不稳定(MSI-L)；当四个MMR蛋白中有2个或2个以上发生表达缺失时，判为高度微卫星不稳定(MSI-H)。</p><p>聚合酶链反应(PCR)：PCR是通过荧光引物和毛细管电泳对微卫星重复体进行扩增，并对正常细胞与肿瘤细胞中的扩增结果进行比较。国家癌症研究所推荐使用BAT-25、BAT-26两个单核苷酸标志物位点和D2S123、D5S346和D17S250三个双核苷酸标志物位点。然而，目前广泛应用的标志物组合为单核苷酸BAT-25、BAT-26、NR-21、NR24、NR22或NR27。当标志物均未发现异常，则定义为MSS；当标本 &lt; 40%的微卫星标志物异常时，则定义为MSI-L；当标本 ≥ 40%的微卫星标志物异常时，则定义为MSI-H。</p><p>目前，Hsp110 T17E-ice-COLD-PCR检测方法是常规PCR技术的一项重大改进。该方法使用了单核苷酸DNA重复序列Hsp110T17以及一种与野生基因型互补的LAN阻滞探针 [<xref ref-type="bibr" rid="hanspub.38529-ref14">14</xref>]。与使用HT17的标准PCR相比，该检测可显著提高MSI检测的准确性。</p><p>基于二代高通量测序(NGS)技术可分为两类：突变负担法和读取计数分布法。突变负担法需要数万个昂贵的基因测序模板，甚至需要进行全基因组的分析，因为小数量的模板计算可能会偏离其真实价值，因此在临床实践中受到诸多限制。相比之下，基于读取计数分布法的MSI分析更适于临床实践，它不仅显示出与基因检测的高度一致性，而且，它与更便宜、更高效的测序模板具有兼容性 [<xref ref-type="bibr" rid="hanspub.38529-ref15">15</xref>]。新一代测序技术的不断进展使得识别人类MSI肿瘤的所有基因改变成为了可能，为MSI肿瘤的筛查提供了新的方法。</p></sec><sec id="s10"><title>6. Lynch综合征相关性结直肠癌</title><p>Lynch综合征曾被命名为遗传性非息肉病性结直肠癌(HNPCC)，主要是由胚系突变引起的，是一种常染色体显性遗传病。Lynch综合征(LS)结直肠癌的发生主要是因为DNA错配修复(MMR)系统的基因缺陷，其中多数为MLH1、MSH2、MSH6和PMS2等DNA错配修复(MMR)基因的胚系突变。MSH2和MLH1对于自身异二聚体伴侣的稳定性是必需的，造成必需蛋白MSH2或MLH1丢失的突变分别导致MSH6和PMS2的降解与丢失，然而，MSH6或PMS2的有害突变将只导致MSH6或PMS2的自身的丢失 [<xref ref-type="bibr" rid="hanspub.38529-ref16">16</xref>]。另外，约有3%的LS是由于MSH2上游的EPCAM基因3′末端外显子缺失导致MSH2基因启动子高甲基化所致。此外，常规方法无法检测到的胚系MSH2外显子易位，成为LS的另一个原因 [<xref ref-type="bibr" rid="hanspub.38529-ref17">17</xref>]。这些胚系突变进而导致MMR蛋白水平降低，从而加速新生体细胞突变的发生或损害MMR基因的其他功能，如凋亡信号，从而增加恶性肿瘤的风险 [<xref ref-type="bibr" rid="hanspub.38529-ref18">18</xref>]。</p><p>二次打击 [<xref ref-type="bibr" rid="hanspub.38529-ref19">19</xref>] 学说认为：所有的肿瘤至少都会经历两次突变才会向肿瘤转变。遗传性结直肠癌患者由于出生时已携带一个突变的等位基因，再经历一次基因突变便会发生癌变，相对于出生无等位基因突变的散发性结直肠癌患者更易发生恶性肿瘤。各项研究表明，Lynch综合征患者易诱发各种癌症，患者终生CRC以及胃癌、肝癌、胰腺癌、胆道癌、小肠癌、泌尿道癌、脑癌和皮肤癌的风险均增加。其中，CRC的患病率最高，达到了52%~82%；此外，女性约有4%~12%的概率患卵巢癌及25%~60%的概率患子宫内膜癌 [<xref ref-type="bibr" rid="hanspub.38529-ref20">20</xref>]。因此，了解Lynch综合征与MSI的相关性，筛查Lynch综合征患者，及早进行监测与干预，一定程度上可预防癌症的发生。</p><p>LS的筛查方法经历了不断的改进。传统上，获得准确的家族史可以有针对性的识别LS的风险人群。 目前较为流行的指南方法包括Amsterdam II标准和修订后的Bethesda指南：Amsterdam II标准对LS诊断的敏感性和特异性分别为22%和98%，而修订后的Bethesda指南由于纳入了切除癌的组织病理学特征，诊断的灵敏度提高到了82%，而特异性为77% [<xref ref-type="bibr" rid="hanspub.38529-ref21">21</xref>]。</p><p>目前，LS最为准确的筛查方法是对错配修复基因进行测序。但是，由于基因测序价格昂贵，而免疫组化具有价格低廉，操作简单快速的特点，因此，在实际工作中，首先应用免疫组化检测错配修复蛋白进行初步筛查。当样本为MSS时，患者不可能患林奇综合征，不必进行基因测序筛查Lynch综合征；当样本为MSI-L时，绝大部分患者不可能患有林奇综合征；当样本确定为MSI-H时，患者患有林奇综合征的可能性极高，需进一步进行林奇综合征的筛查诊断。</p><p>绝大多数散发性MSI相关性结直肠癌是由于MLH1启动子区域甲基化造成的，并且这部分患者常伴随BRAF (通常为V600E)的突变，而Lynch综合征患者大多数未发现BRAF的突变 [<xref ref-type="bibr" rid="hanspub.38529-ref22">22</xref>]，仅有1%的MLH1缺失的LS患者为BRAF基因V600E突变 [<xref ref-type="bibr" rid="hanspub.38529-ref23">23</xref>]。近年来，由于BRAF V600E抗体的问世，对BRAF V600E的检测变得迅速而快捷 [<xref ref-type="bibr" rid="hanspub.38529-ref24">24</xref>]。因此，对MLH1蛋白缺失患者进行MLH1启动子甲基化检测和BRAF V600E免疫组化检测可将LS与散发性MSI-H结肠癌区分开来。二代高通量测序(NGS)检测标准中已明确指出：MSI阳性，且BRAF V600E和MHL1甲基化检测阴性的患者适合进行NGS的检测 [<xref ref-type="bibr" rid="hanspub.38529-ref25">25</xref>]。</p></sec><sec id="s11"><title>7. 研究展望</title><p>结直肠癌的发病原因和发病机制较为复杂，而微卫星不稳定的发现进一步增加了人们对结直肠癌的认识，目前，微卫星的检测在结直肠癌中较为普遍，微卫星的状态可以预测免疫治疗敏感性，指导临床治疗，并能预测患者预后。</p><p>目前，LS患者的检测主要还是依靠传统的临床定义，但是为了识别这些患者，越来越多地提倡对新诊断的结直肠癌进行MMR/MSI检测 [<xref ref-type="bibr" rid="hanspub.38529-ref26">26</xref>]，这种识别对于正确治疗和监视个人及其家人至关重要。许多国家已经实施了基于人群的肠癌筛查 [<xref ref-type="bibr" rid="hanspub.38529-ref27">27</xref>]，通过筛查LS并内镜切除高级别腺瘤可以预防CRC。</p><p>研究表明：DNA错配修复缺陷(dMMR)是LS相关致癌的早期事件，基于此，对腺瘤的dMMR/MSI检测将有助于LS的筛查。多项研究 [<xref ref-type="bibr" rid="hanspub.38529-ref28">28</xref>] 表明dMMR/MSI检测腺瘤在LS的诊断中具有一定价值，但是，由于研究规模较小且腺瘤中dMMR/MSI发病率较低，这些研究尚未达成共识。</p><p>因此，明确结直肠癌及腺瘤等癌前病变的微卫星状态、BRAF等基因的表达情况，寻找它们之间的相关性，将有助于LS的筛查，对结直肠癌的发生进行提前干预，这对于癌症的预防及治疗具有重要价值。</p></sec><sec id="s12"><title>文章引用</title><p>郑 雪,邹佳芮,李宝华,张亚楠,解水杉,郝俊梅. 微卫星不稳定性与结直肠癌及癌前病变相关性研究进展Research Progress on the Relationship between Microsatellite Instability and Colorectal Cancer and Precancerous Lesions[J]. 临床医学进展, 2020, 10(11): 2471-2477. https://doi.org/10.12677/ACM.2020.1011373</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38529-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Keum, N. and Giovannucci, E. (2019) Global Burden of Colorectal Cancer: Emerging Trends, Risk Factors and Prevention Strategies. Nature Reviews. Gastroenterology &amp; Hepatology, 16, 713-732.  
&lt;br&gt;https://doi.org/10.1038/s41575-019-0189-8</mixed-citation></ref><ref id="hanspub.38529-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Sinicrope, F.A. and Sargent, D.J. (2012) Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications. Clinical Cancer Research, 18, 1506-1512.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-11-1469</mixed-citation></ref><ref id="hanspub.38529-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Evrard, C., Tachon, G., Randrian, V., et al. (2019) Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. Cancers (Basel), 11, 1567. &lt;br&gt;https://doi.org/10.3390/cancers11101567</mixed-citation></ref><ref id="hanspub.38529-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., et al. (2017) Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. International Journal of Molecular Sciences, 18, 197.  
&lt;br&gt;https://doi.org/10.3390/ijms18010197</mixed-citation></ref><ref id="hanspub.38529-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Battaglin, F., Naseem, M., Lenz, H., et al. (2018) Microsatellite Instability in Colorectal Cancer: Overview of Its Clinical Significance and Novel Perspectives. Clinical Advances in Hematology &amp; Oncology, 16, 735.</mixed-citation></ref><ref id="hanspub.38529-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Seth, S., Ager, A., Arends, M.J., et al. (2018) Lynch Syndrome—Cancer Pathways, Heterogeneity and Immune Escape. The Journal of Pathology, 246, 129-133. &lt;br&gt;https://doi.org/10.1002/path.5139</mixed-citation></ref><ref id="hanspub.38529-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Jonchere, V., Marisa, L., Greene, M., et al. (2018) Identification of Positively and Negatively Selected Driver Gene Mutations Associated with Colorectal Cancer with Microsatellite Instability. Cellular and Molecular Gastroenterology and Hepatology, 6, 277-300. &lt;br&gt;https://doi.org/10.1016/j.jcmgh.2018.06.002</mixed-citation></ref><ref id="hanspub.38529-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chen, E., Xu, X. and Liu, T. (2018) Hereditary Nonpolyposis Colorectal Cancer and Cancer Syndromes: Recent Basic and Clinical Discoveries. Journal of Oncology, 2018, 3979111-3979135. &lt;br&gt;https://doi.org/10.1155/2018/3979135</mixed-citation></ref><ref id="hanspub.38529-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ahmed, M. (2020) Colon Cancer: A Clinician’s Perspective in 2019. Gastroenterology Research, 13, 1-10.  
&lt;br&gt;https://doi.org/10.14740/gr1239</mixed-citation></ref><ref id="hanspub.38529-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">O’Brien, M.J., Zhao, Q. and Yang, S. (2015) Colorectal Serrated Pathway Cancers and Precursors. Histopathology, 66, 49-65. &lt;br&gt;https://doi.org/10.1111/his.12564</mixed-citation></ref><ref id="hanspub.38529-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ahadova, A., Gallon, R., Gebert, J., et al. (2018) Three Molecular Pathways Model Colorectal Carcinogenesis in Lynch Syndrome. International Journal of Cancer, 143, 139-150. &lt;br&gt;https://doi.org/10.1002/ijc.31300</mixed-citation></ref><ref id="hanspub.38529-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ma, H., Brosens, L.A.A., Offerhaus, G.J.A., et al. (2018) Pathology and Genetics of Hereditary Colorectal Cancer. Pathology, 50, 49-59. &lt;br&gt;https://doi.org/10.1016/j.pathol.2017.09.004</mixed-citation></ref><ref id="hanspub.38529-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Dabir, P.D., Bruggeling, C.E., van der Post, R.S., et al. (2020) Microsatellite Instability Screening in Colorectal Adenomas to Detect Lynch Syndrome Patients? A Systematic Review and Meta-Analysis. European Journal of Human Genetics, 28, 277-286. &lt;br&gt;https://doi.org/10.1038/s41431-019-0538-7</mixed-citation></ref><ref id="hanspub.38529-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">How-Kit, A., Daunay, A., Buhard, O., et al. (2018) Major Improvement in the Detection of Microsatellite Instability in Colorectal Cancer Using HSP110 T17 E-Ice-COLD-PCR. Human Mutation, 39, 441-453.  
&lt;br&gt;https://doi.org/10.1002/humu.23379</mixed-citation></ref><ref id="hanspub.38529-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, L., Huang, Y., Fang, X., et al. (2018) A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing. The Journal of Molecular Diagnostics, 20, 225-231.  
&lt;br&gt;https://doi.org/10.1016/j.jmoldx.2017.11.007</mixed-citation></ref><ref id="hanspub.38529-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Paredes, S.R., Chan, C. and Rickard, M. (2020) Immunohistochemistry in Screening for Heritable Colorectal Cancer: What to Do with an Abnormal Result. ANZ Journal of Surgery, 90, 702-707. &lt;br&gt;https://doi.org/10.1111/ans.15586</mixed-citation></ref><ref id="hanspub.38529-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Rhees, J., Arnold, M. and Boland, C.R. (2014) Inversion of Exons 1-7 of the MSH2 Gene Is a Frequent Cause of Unexplained Lynch Syndrome in One Local Population. Familial Cancer, 13, 219-225.  
&lt;br&gt;https://doi.org/10.1007/s10689-013-9688-x</mixed-citation></ref><ref id="hanspub.38529-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Mäki-Nevala, S., Valo, S., Ristimäki, A., et al. (2019) DNA Methylation Changes and Somatic Mutations as Tumorigenic Events in Lynch Syndrome-Associated Adenomas Retaining Mismatch Repair Protein Expression. EBioMedicine, 39, 280-291. &lt;br&gt;https://doi.org/10.1016/j.ebiom.2018.12.018</mixed-citation></ref><ref id="hanspub.38529-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Bandinelli, L.P., Levandowski, M.L. and Grassi-Oliveira, R. (2017) The Childhood Maltreatment Influences on Breast Cancer Patients: A Second Wave Hit Model Hypothesis for Distinct Biological and Behavioral Response. Medical Hypotheses, 108, 86-93. &lt;br&gt;https://doi.org/10.1016/j.mehy.2017.08.007</mixed-citation></ref><ref id="hanspub.38529-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Yılmaz, A., Mirili, C., Bilici, M., et al. (2020) Colorectal Cancer in Lynch Syndrome Associated with PMS2 and MSH6 Mutations. International Journal of Colorectal Disease, 35, 351-353.  
&lt;br&gt;https://doi.org/10.1007/s00384-019-03454-4</mixed-citation></ref><ref id="hanspub.38529-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ladabaum, U., Wang, G., Terdiman, J., et al. (2011) Strategies to Identify the Lynch Syndrome among Patients with Colorectal Cancer: A Cost-Effectiveness Analysis. Annals of Internal Medicine, 155, 69-79.  
&lt;br&gt;https://doi.org/10.7326/0003-4819-155-2-201107190-00002</mixed-citation></ref><ref id="hanspub.38529-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Parsons, M.T., Buchanan, D.D., Thompson, B., et al. (2012) Correlation of Tumour BRAF Mutations and MLH1 Methylation with Germline Mismatch Repair (MMR) Gene Mutation Status: A Literature Review Assessing Utility of Tumour Features for MMR Variant Classification. Journal of Medical Genetics, 49, 151-157.  
&lt;br&gt;https://doi.org/10.1136/jmedgenet-2011-100714</mixed-citation></ref><ref id="hanspub.38529-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">白雪杉, 林国乐. V1版《NCCN结直肠癌诊治指南》更新要点解析[J]. 中国全科医学, 2019, 22(33): 4031-4034.</mixed-citation></ref><ref id="hanspub.38529-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Capper, D., Voigt, A., Bozukova, G., et al. (2013) BRAF V600E-Specific Immunohistochemistry for the Exclusion of Lynch Syndrome in MSI-H Colorectal Cancer. International Journal of Cancer, 133, 1624-1630.  
&lt;br&gt;https://doi.org/10.1002/ijc.28183</mixed-citation></ref><ref id="hanspub.38529-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Kašubová, I., Holubeková, V., Janíková, K., et al. (2018) Next Generation Sequencing in Molecular Diagnosis of Lynch Syndrome—A Pilot Study Using New Stratification Criteria. Acta Medica (Hradec Kralove, Czech Republic), 61, 98-102. &lt;br&gt;https://doi.org/10.14712/18059694.2018.125</mixed-citation></ref><ref id="hanspub.38529-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Leenen, C.H.M., Goverde, A., de Bekker-Grob, E.W., et al. (2016) Cost-Effectiveness of Routine Screening for Lynch Syndrome in Colorectal Cancer Patients Up to 70 Years of Age. Genetics in Medicine, 18, 966-973.  
&lt;br&gt;https://doi.org/10.1038/gim.2015.206</mixed-citation></ref><ref id="hanspub.38529-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Navarro, M., Nicolas, A., Ferrandez, A., et al. (2017) Colorectal Cancer Population Screening Programs Worldwide in 2016: An Update. World Journal of Gastroenterology, 23, 3632. &lt;br&gt;https://doi.org/10.3748/wjg.v23.i20.3632</mixed-citation></ref><ref id="hanspub.38529-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Mendelsohn, R.B., Herzog, K., Shia, J., et al. (2017) Molecular Screening for Lynch Syndrome in Young Patients with Colorectal Adenomas. Clinical Colorectal Cancer, 16, 173-177. &lt;br&gt;https://doi.org/10.1016/j.clcc.2017.01.002</mixed-citation></ref></ref-list></back></article>